Deal struck for production of anti-cancer drug for clinical trials

Deal struck for production of anti-cancer drug for clinical trials

Redx Pharma has struck a deal with a fellow a Cheshire company to supply its Porcupine inhibitor – which tackles hard-to-treat cancers for clinical trials.

Porcupine (RXC004) battles pancreative, triple negative breast and head and neck cancers. First in-human studies are expected to start early in 2017.

The deal is with Quay Pharma which will manufacture RXC004.

The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway implicated in the maintenance of cancer stem cells associated with tumorigenesis, metastasis, recurrence and resistance in several types of cancer.

Neil Murray, chief executive of Redx, said: “We are pleased to confirm that we remain on track to enter the clinical trial phase for our Porcupine program in the first quarter of 2017. Our Porcupine inhibitor is an especially exciting clinical candidate, both scientifically and commercially.”


See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.